Timm Bauer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1371203/publications.pdf Version: 2024-02-01



TIMM RALIED

#	Article	IF	CITATIONS
1	Fiveâ€year followâ€up of patients who underwent everolimusâ€eluting bioresorbable scaffold implantation. Catheterization and Cardiovascular Interventions, 2021, 97, 56-62.	1.7	0
2	CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension. European Respiratory Journal, 2021, 57, 1901192.	6.7	15
3	Transcatheter or surgical aortic valve implantation in chronic dialysis patients: a German Aortic Valve Registry analysis. Clinical Research in Cardiology, 2021, 110, 357-367.	3.3	11
4	Incidence and outcome of peri-procedural cardiogenic shock: results from the international Euro Heart Survey PCI registry. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 120-127.	1.0	4
5	Impact of preprocedural TIMI flow on clinical outcome in lowâ€risk patients with STâ€elevation myocardial infarction: Results from the ATLANTIC study. Catheterization and Cardiovascular Interventions, 2020, 95, 494-500.	1.7	12
6	Impact of new pacemaker implantation following surgical and transcatheter aortic valve replacement on 1-year outcome. European Journal of Cardio-thoracic Surgery, 2020, 57, 151-159.	1.4	55
7	Fractional flow reserve and frequency of PCI in patients with coronary artery disease. Herz, 2020, 45, 752-758.	1.1	0
8	Prognostic Impact of Underweight (Body Mass Index <20 kg/m2) in Patients With Severe Aortic Valve Stenosis Undergoing Transcatheter Aortic Valve Implantation or Surgical Aortic Valve Replacement (from the German Aortic Valve Registry [GARY]). American Journal of Cardiology, 2020, 129, 79-86.	1.6	17
9	OCTâ€assessment of scaffold resorption: Analysis of strut intensity by a new resorption index for poly―l ″actic acid bioresorbable vascular scaffolds. Catheterization and Cardiovascular Interventions, 2019, 94, 928-935.	1.7	0
10	Effect of Plaque Composition, Morphology, and Burden on DESolve Novolimus-Eluting Bioresorbable Vascular Scaffold Expansion and Eccentricity — An Optical Coherence Tomography Analysis. Cardiovascular Revascularization Medicine, 2019, 20, 480-484.	0.8	4
11	A multicenter postâ€marketing evaluation of the Elixir DESolve [®] Novolimusâ€eluting bioresorbable coronary scaffold system: First results from the DESolve PMCF study. Catheterization and Cardiovascular Interventions, 2018, 92, 1021-1027.	1.7	21
12	Specific biomarkers of myocardial inflammation and remodeling processes as predictors of mortality in highâ€risk patients undergoing percutaneous mitral valve repair (MitraClip). Clinical Cardiology, 2018, 41, 481-487.	1.8	11
13	Trends in practice and outcomes from 2011 to 2015 for surgical aortic valve replacement: an update from the German Aortic Valve Registry on 42Â776 patients. European Journal of Cardio-thoracic Surgery, 2018, 53, 552-559.	1.4	71
14	Rapid Deployment Versus Conventional Bioprosthetic Valve Replacement for Aortic Stenosis. Journal of the American College of Cardiology, 2018, 71, 1417-1428.	2.8	100
15	Evaluation of cystatin C and neutrophil gelatinaseâ€associated lipocalin as predictors of mortality in patients undergoing percutaneous mitral valve repair (MitraClip). Clinical Cardiology, 2018, 41, 1474-1479.	1.8	4
16	Galectinâ€3 and ST2 as predictors of therapeutic success in highâ€risk patients undergoing percutaneous mitral valve repair (MitraClip). Clinical Cardiology, 2018, 41, 1164-1169.	1.8	6
17	Everolimus- Versus Novolimus-Eluting Bioresorbable Scaffolds for the TreatmentÂof Coronary Artery Disease. JACC: Cardiovascular Interventions, 2017, 10, 477-485.	2.9	12
18	Impact of strut thickness on acute mechanical performance: A comparison study using optical coherence tomography between DESolve 150 and DESolve 100. International Journal of Cardiology, 2017, 246, 74-79.	1.7	10

TIMM BAUER

#	Article	IF	CITATIONS
19	Post-dilatation after implantation of bioresorbable everolimus- and novolimus-eluting scaffolds: an observational optical coherence tomography study of acute mechanical effects. Clinical Research in Cardiology, 2017, 106, 271-279.	3.3	6
20	Thebesian veins as drainage to the ventricle: A case report. Cardiovascular Revascularization Medicine, 2017, 18, 213-214.	0.8	2
21	Bioresorbable scaffold implantation in patients with indication for oral anticoagulation: A propensity matched analysis. International Journal of Cardiology, 2017, 231, 73-77.	1.7	0
22	Outcome After Long-segment Stenting With Everolimus-eluting Bioresorbable Scaffolds Focusing on the Concept of Overlapping Implantation. Revista Espanola De Cardiologia (English Ed), 2016, 69, 1144-1151.	0.6	1
23	Everolimus-eluting bioresorbable scaffold implantation for the treatment of bifurcation lesions — Implications from early clinical experience during daily practice. Cardiovascular Revascularization Medicine, 2016, 17, 313-317.	0.8	6
24	A new novolimus-eluting bioresorbable scaffold for large coronary arteries: an OCT study of acute mechanical performance. International Journal of Cardiology, 2016, 220, 706-710.	1.7	7
25	Use and outcome of thrombus aspiration in patients with primary PCI for acute ST-elevation myocardial infarction: results from the multinational Euro Heart Survey PCI Registry. Heart and Vessels, 2016, 31, 1438-1445.	1.2	8
26	Cardiac Troponin I: A Valuable Biomarker Indicating the Cardiac Involvement in Fabry Disease. PLoS ONE, 2016, 11, e0157640.	2.5	14
27	Use and outcome of radial versus femoral approach for primary PCI in patients with acute ST elevation myocardial infarction without cardiogenic shock: Results from the ALKK PCI registry. Catheterization and Cardiovascular Interventions, 2015, 86, S8-14.	1.7	28
28	Implantation of everolimusâ€eluting bioresorbable scaffolds in a diabetic allâ€comers population. Catheterization and Cardiovascular Interventions, 2015, 86, 975-981.	1.7	8
29	Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation. Clinical Research in Cardiology, 2015, 104, 1064-1071.	3.3	21
30	Impact of the learning curve on procedural results and acute outcome after percutaneous coronary interventions with everolimus-eluting bioresorbable scaffolds in an all-comers population. Cardiovascular Revascularization Medicine, 2015, 16, 455-460.	0.8	17
31	Influence of Renal Sympathetic Denervation on Cardiac Extracellular Matrix Turnover and Cardiac Fibrosis. American Journal of Hypertension, 2015, 28, 1285-1292.	2.0	15
32	Fate of Patients With Coronary Perforation Complicating Percutaneous Coronary Intervention (from) Tj ETQq0 0 Cardiology, 2015, 116, 1363-1367.	0 rgBT /Ov 1.6	verlock 10 Tf 25
33	Feasibility of everolimus-eluting bioresorbable vascular scaffolds in patients with chronic total occlusion. International Journal of Cardiology, 2015, 179, 90-94.	1.7	26
34	Comparison of the Effectiveness of Transcatheter Aortic Valve Implantation in Patients With Stenotic Bicuspid Versus Tricuspid Aortic Valves (from the German TAVI Registry). American Journal of Cardiology, 2014, 113, 518-521.	1.6	125
35	Prima-vista multi-vessel percutaneous coronary intervention in haemodynamically stable patients with acute coronary syndromes: Analysis of over 4.400 patients in the EHS-PCI registry. International Journal of Cardiology, 2013, 166, 596-600.	1.7	29
36	Left circumflex artery-related myocardial infarction: Does ST elevation matter? Results from the Euro Heart Survey PCI registry. International Journal of Cardiology, 2013, 168, 5239-5242.	1.7	4

TIMM BAUER

#	Article	IF	CITATIONS
37	Incidence and Clinical Impact of Stroke Complicating Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2013, 6, 362-369.	3.9	50
38	Multivessel percutaneous coronary intervention in patients with stable angina: a common approach? Lessons learned from the EHS PCI registry. Heart and Vessels, 2012, 27, 453-459.	1.2	8
39	Use and Outcomes of Multivessel Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock (from the EHS-PCI Registry). American Journal of Cardiology, 2012, 109, 941-946.	1.6	84
40	Predictors of hospital mortality in the elderly undergoing percutaneous coronary intervention for acute coronary syndromes and stable angina. International Journal of Cardiology, 2011, 151, 164-169.	1.7	66
41	Direct admission versus transfer of AMI patients for primary PCI. Clinical Research in Cardiology, 2011, 100, 217-225.	3.3	16
42	Comparison between on-label versus off-label use of drug-eluting coronary stents in clinical practice: results from the German DES.DE-Registry. Clinical Research in Cardiology, 2011, 100, 701-709.	3.3	10
43	Impact of diabetes mellitus status on coronary pathoanatomy and interventional treatment: Insights from the Euro heart survey PCI registry. Catheterization and Cardiovascular Interventions, 2011, 78, 702-709.	1.7	13
44	Use of platelet glycoprotein IIb/IIIa inhibitors in diabetics undergoing PCI for non-ST-segment elevation acute coronary syndromes: impact of clinical status and procedural characteristics. Clinical Research in Cardiology, 2010, 99, 375-383.	3.3	7
45	Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 576-581.	2.8	43
46	Efficacy of a 24-h primary percutaneous coronary intervention service on outcome in patients with ST elevation myocardial infarction in clinical practice. Clinical Research in Cardiology, 2009, 98, 171-178.	3.3	24
47	Gender differences in patients with acute ST-elevation myocardial infarction complicated by cardiogenic shock. Clinical Research in Cardiology, 2009, 98, 781-786.	3.3	43
48	Impact of Chronic Antithrombotic Therapy on Hospital Course of Patients with Acute Myocardial Infarction. Clinical Cardiology, 2009, 32, 718-723.	1.8	3
49	Effect of Chronic Statin Pretreatment on Hospital Outcome in Patients With Acute Non-ST-Elevation Myocardial Infarction. Journal of Cardiovascular Pharmacology, 2009, 53, 132-136.	1.9	17
50	Effect of an invasive strategy on in-hospital outcome in elderly patients with non-ST-elevation myocardial infarction. European Heart Journal, 2007, 28, 2873-2878.	2.2	124